News

Novel Therapy For Glioblastoma brain cancer displays positive outcomes

Jun, 2021 - By WMR

Novel Therapy For Glioblastoma brain cancer displays positive outcomes

Lisavanbulin is amongst the several novel drugs in progress designed for inhibiting tumor growth along with treating this devastating cancer form.

Recently announced results of an initial clinical trial analyzing a kind of novel drug for brain cancer drug revealed extremely promising responses within a specific patient subset. A bigger Phase 2 trial is currently underway pursuing patients having a particular biomarker. Glioblastoma is often a deadly and aggressive brain cancer form, with survival of just nearly 5% patients more than 5 years after first diagnosis. The Lisavanbulin is amongst the several novel drugs in progress designed for inhibiting tumor growth along with treating this devastating cancer form.

Data of long-term from a newly completed human trial of Phase 1 initially exposed mixed results, with just two among 20 patients displaying significant improvements. However, after a closer look at this data, the scientists found those 2 successful cases had a specific characteristic. The two patients were discovered of having a particular protein’s high expression known as end-binding protein 1 (EB1) within their tumor’s tissue. Three among the 20 subjects of this initial trial displayed strong expression of EB1. Preclinical studies even found positivity of EB1 was a solid efficacy predictor. After these results a trial of Phase 2 is presently underway focusing specifically on patients of glioblastoma with tumors that are EB1-positive.

Latest findings showed at the latest American Society of Clinical Oncology (ASCO) Annual Meeting specify EB1 expression could be present in approximately 5% cases of glioblastoma. The research even looked at the expression of EB1 in the number of other samples of cancer, finding it in little levels within certain metastatic melanoma, breast cancer and lung cancer tissues. Amongst this early trial’s patients, Paul Nicholson, experienced a shrinkage in his cancer by over 80 %. After three years his scans still look positive. The international Phase 2 trial’s Initial results are expected towards the end of this year.

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Contact us

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports, 403, 4th Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).


Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2021 Worldwide Market Reports. All rights reserved